Eupraxia Pharmaceuticals reported free cash flow of $0.00B for the quarter ended Jun 2026. This cash flow statement covers 14 quarters of results from Mar 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Net Income | -0.00B | -0.01B | -0.00B | -0.01B | -0.01B | -0.01B | -0.01B | -0.01B | -0.01B | -0.01B | -0.01B | -0.02B | -0.01B | -0.01B |
| Depreciation and Depletion | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | ||
| Share-based Compensation | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.01B | 0.00B | 0.00B |
| Gains from Sales and Divestitures | 138.00 | 0.00B | 188.00 | -0.00B | 0.00B | 0.00B | ||||||||
| Cash from Operations | -0.01B | -0.01B | -0.01B | -0.01B | ||||||||||
| Depreciation, Depletion & Amortization | ||||||||||||||
| Depreciation & Amortization (CF)Depreciation & Amortization | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | ||
| Change in Working Capital | ||||||||||||||
| Change in Receivables | 0.00B | 0.00B | -0.00B | -0.00B | 0.00B | 0.00B | 0.00B | -0.00B | -0.00B | 0.00B | -0.00B | -0.00B | 0.00B | -0.00B |
| Change in Accured Expenses | -0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 1,865.71B | -1865.71B | 0.00B | -0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| Other Working Capital Changes | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 867.00 | 0.00B | 0.00B | 0.00B | |
| Investing Activities | ||||||||||||||
| Capital Expenditures | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B |
| Sales of Property, Plant and Equipment | 558.00 | |||||||||||||
| Change in Acquisitions & Divestments | -0.08B | |||||||||||||
| Cash from Investing Activities | -0.00B | -0.00B | -0.00B | -0.00B | ||||||||||
| Financing Activities | ||||||||||||||
| Debt Issuance and Repayment | ||||||||||||||
| Long-Term Debt Repayments | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | -0.00B | |
| Change in Capital Stock | ||||||||||||||
| Net Equity Issued and Repurchased | 0.00B | 0.00B | 0.00B | -1.00 | 0.02B | -0.02B | 0.02B | 0.00B | 0.00B | 0.00B | 0.07B | 0.00B | 0.05B | |
| Misc. | ||||||||||||||
| Cash from Financing Activities | 0.02B | 0.00B | 0.03B | 0.00B | ||||||||||
| Exchange Rate Effect | -0.00B | 0.00B | -0.00B | 0.00B | -0.00B | |||||||||
| Change in Cash | 0.01B | -0.01B | 0.01B | -0.04B | ||||||||||
| Beginning Cash Balance | 0.02B | -8.00 | 0.02B | 0.03B | 0.08B | |||||||||
| Free Cash Flow | 0.00B | 0.00B | -0.01B | -0.01B | 0.00B | 0.00B | 0.00B | -0.01B | 0.00B | 0.00B | 0.00B | -0.01B | 0.00B | 0.00B |
| Net Cash Flow | 0.01B | -0.01B | 0.03B | -0.01B |
Pull Eupraxia Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=EPRX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "EPRX", "statement": "CF", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=EPRX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();